The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
A recent study revealed a 17.5% increase in asthma-related hospitalizations in the three months following the announcement that GSK would discontinue the widely used asthma medication Flovent, and ...